Illumina's New CEO to Focus on Software as Flatley Takes on Reimbursement

Jun 16, 2016

|

Premium

NEW YORK (GenomeWeb) – Software is becoming an increasingly important part of Illumina's business, and will be a key focus of current President Francis deSouza when he takes the helm as CEO in July, current CEO Jay Flatley said in a Q&A at Goldman Sachs' Global Healthcare Conference last week, which was webcast.

Flatley, meantime, will stay on as executive chairman of Illumina and said that part of his role would involve tackling the reimbursement challenges for clinical next-generation sequencing products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Featured White Papers

Combined Analysis of CNVs and SNVs in Genomic Diagnostics

Authenticating human cell lines using the Identifiler kits and capillary electrophoresis platforms

Detect low-level somatic mutations in FFPE samples using an extended RAS research assay

MLPA Assays on the SeqStudio Genetic Analyzer

Apr

25

Featured Webinar

A High-Sensitivity, Clone-Specific Strategy to Evaluate Minimal Residual Disease in AML

This webinar will share details from a study at the Saint-Antoine Research Center, Sorbonne University to test the feasibility of a high-sensitivity, clone-specific strategy for evaluating minimal residual disease (MRD) in acute myeloid leukemia (AML).

Apr

26

Featured Webinar

Evaluation of a Pan-Cancer Cell-Free Assay to Meet Unmet Research Needs

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

May

01

Featured Webinar

Analytical Validation of a Liquid Biopsy Assay for High-Sensitivity Molecular Profiling

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May

03

Featured Webinar

GenomeWeb/ABRF 2018 Webinar Series: Novel Tools for Multidimensional Profiling of Single Cells

This webinar will introduce new technologies that enable multidimensional measurements from single cells to obtain a more complete picture of a cell’s phenotype and gene expression.

Main menu